Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: Two-year follow-up of the prevention of coronary sclerosis study

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 6, 2001, Pages 473-485

  Sato, Shinichi ^a   Kobayashi, Tohru ^a   Awata, Nobuhisa ^a   Reiber, Johan H C ^b   Nakagawa, Yumiko ^a   Hiraoka, Hisatoyo ^a   Katoh, Osamu ^a   Kirino, Motohiro ^a   Kobayashi, Tomoko ^a   Iida, Minoru ^a   Itoh, Tadao ^c   Shibata, Nobuhiko ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Coronary heart disease; Normocholesterolemia; Pravastatin; Prevention; Quantitative coronary arteriography

Indexed keywords

CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SECONDARY PREVENTION;

EID: 0034990850     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80058-8     Document Type: Article

References (38)

1. Mortality by cause for eight regions of the world: Global Burden of Disease Study
2. Serum cholesterol, lipoproteins and the risk of coronary heart disease: The Framingham Study
3. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: Final report of the Pooling Project
4. An update on coronary risk factors
5. The trend of coronary heart disease and its risk factors based on epidemiological investigations
6. Trend of coronary heart disease and its relationship to risk factors in a Japanese population: A 26-year follow up, Hiroshima/Nagasaki Study
7. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
9. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
10. Range of serum cholesterol values in the population developing coronary artery disease
11. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association
12. Recommendations for human blood pressure determination by sphygmomanometers. Subcommittee of the AHA Post-graduate Education Committee
13. Point: Status of lipid and lipoprotein standardization
14. State of the art in quantitative coronary arteriography as of 1996
15. Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
16. Long-term outcome of patients with asymptomatic restenosis after percutaneous transluminal coronary angioplasty
17. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test
18. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
19. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypercholesterolemic therapy on coronary atherosclerosis in angiographic trials
20. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
21. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
22. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS)
23. Effect of pravastatin on outcomes after cardiac transplantation
24. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages
25. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
26. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
27. The Kuopio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins and atherosclerotic progression
28. Platelet-dependent thrombin generation in patients with hyperlipidemia
29. 2+ and membrane dynamics in patients with primary hypercholesterolemia: Effects of pravastatin
30. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
31. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients
32. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I)
33. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC 1): Reduction in atherosclerosis progression and clinical events. PLAC 1 investigation
34. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program
35. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
36. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
37. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris
38. The P.P.P. Project Investigators. Design, rationale and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project - A combined analysis of three large-scale randomized trials: Long-Term Investigation with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE) and West of Scotland Coronary Prevention Study (WOSCOPS)